

# **Market Announcement**

22 May 2023

## Pharmaxis Ltd (ASX: PXS) - Trading Halt

### **Description**

The securities of Pharmaxis Ltd ('PXS') will be placed in trading halt at the request of PXS, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 24 May 2023 or when the announcement is released to the market.

### **Issued by**

#### Lisa Banh

Senior Adviser, Listings Compliance



22 May 2023

ASX Compliance Pty Limited 20 Bridge Street Sydney NSW 2000

#### Pharmaxis Ltd (ASX: PXS) - Request for trading halt

Pursuant to ASX Listing Rule 17.1, Pharmaxis Ltd (the **Company**) requests a trading halt in respect of its ordinary shares (ASX: PXS) from the commencement of trading today, Monday 22 May 2023.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- a. The trading halt is requested pending an analysis of data and announcement by the Company to the market in relation to the top line results of an investigator initiated phase 1c clinical trial in established scars (**Clinical Trial**).
- b. The Company requests that the trading halt remains in place until the earlier of commencement of trading on Wednesday 24 May 2023 and the time at which the Company makes an announcement to the market in relation to the outcome of the Clinical Trial.
- c. The Company confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely Pharmaxis Ltd

David McGarvey

Chief Financial Officer / Company Secretary

Authorised for release by the Board of Pharmaxis Ltd.